Filing Flows › Xeris Biopharma Holdings (XERS) › Product revenue, net revenue
Xeris Biopharma Holdings (XERS) Product revenue, net revenue by quarter
Xeris Biopharma Holdings' Product revenue, net revenue was $106M in Q3 2026 (third quarter 2026), +17% from Q2 2026. Over the last 7 quarters it ranged from $57.8M (Q1 2025) to $106M (Q3 2026).
| Quarter | Product revenue, net revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $106M | +17% | +43% |
| Q2 2026 | $91.0M | +10% | +34% |
| Q1 2026 | $82.5M | -1% | +43% |
| Q4 2025 | $83.4M | +13% | — |
| Q3 2025 | $74.1M | +9% | — |
| Q2 2025 | $67.7M | +17% | — |
| Q1 2025 | $57.8M | — | — |
Q3 2026 at a glance
Xeris Biopharma Holdings, Q3 2026: revenue $107M (+44% year over year), operating margin 15.8%, net earnings $11.3M, operating cash flow $35.5M. The chart follows the revenue to costs, profit and cash.
Questions
What is Xeris Biopharma Holdings' Product revenue, net revenue?
Xeris Biopharma Holdings' Product revenue, net revenue was $106M in Q3 2026 (third quarter 2026), +17% from Q2 2026.
How has Xeris Biopharma Holdings' Product revenue, net revenue changed?
Over the last 7 quarters it ranged from $57.8M (Q1 2025) to $106M (Q3 2026).
Q3 2026 results → · How Xeris Biopharma Holdings makes money →